High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 701–800 of 1,001
RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma
Yang, D., Tao, J., Li, L., Kedei, N., Tóth, Z., Czap, A. L., Velasquez, J. F., Mihova, D., Michalowski, A. M., Yuspa, S. H., et al. (2011) · Oncogene · doi:10.1038/onc.2011.166 · Cited by 41
“Thus, mutations in B-Raf are found in some 60% of melanomas and mutations in PTEN, an inhibitor of Akt activity, are found in 30% (Ikediobi et al 2006, Pollock et al 2003, Wu et al 2003).”
BackgroundInfluentialRutkowski, P. L., Gos, A., Jurkowska, M., Świtaj, T., Dziewirski, W., Zdzienicki, M., Ptaszyński, K., Michej, W., Tysarowski, A., & SIEDLECKI, J. A. (2014) · Oncology Letters · doi:10.3892/ol.2014.2122 · Cited by 40
“V600E is not sufficient for the malignant transformation of melanocytes (14) and is an early oncogenic event also found at a high frequency in benign nevi (15).”
Kim, I.-J., Kang, H. C., Jang, S., Kim, K. H., Ahn, S.-A., Yoon, H., Yoon, S. N., & Park, J.-G. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi237 · Cited by 38
Pathways from senescence to melanoma: focus on MITF sumoylation
Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Oncogene · doi:10.1038/onc.2017.292 · Cited by 46
Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology
Mancera, N., Smalley, K. S. M., & Margo, C. E. (2018) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2018.12.002 · Cited by 40
Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
Zhang, X., Tang, J., Vergara, I. A., Zhang, Y., Szeto, P., Yang, L., Mintoff, C., Colebatch, A. J., McIntosh, L., Mitchell, K. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0407 · Cited by 45
Self-citationInduction and transmission of oncogene-induced senescence
Rattanavirotkul, N., Kirschner, K., & Chandra, T. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03638-0 · Cited by 43
Pappo, A. S., McPherson, V. J., Pan, H., Wang, F., Wang, L., Wright, T. S., Hussong, M., Hawkins, D., Kaste, S. C., Davidoff, A. M., et al. (2021) · Cancer · doi:10.1002/cncr.33750 · Cited by 38
“Therefore, it was not surprising to see this genomic aberration because BRAF mutations are found in up to 80% of nevi.(24) In summary, our registry has demonstrated that the use of an integrated clinicopathologic and genomic approach to pediatric melanocytic lesions can optimize their diagnosis and help to better pred…”
BackgroundBRAF Mutation Testing in Colorectal Cancer
Sharma, S. G., & Gulley, M. L. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0232-rs.1 · Cited by 38
Spanjaard, R. A., Whren, K., Graves, C., & Bhawan, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22367 · Cited by 42
The Role of the Hippo Pathway in Melanocytes and Melanoma
Kim, J. E., Finlay, G. J., & Baguley, B. C. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00123 · Cited by 42
“HYPOTHESIS ANDTHEORY ARTICLE published: 16 May 2013 doi: 10.3389/fonc.2013.00123 The role of the Hippo pathway in melanocytes and melanoma”
BackgroundInfluentialHallmarks for senescence in carcinogenesis: novel signaling players
Caino, M. C., Meshki, J., & Kazanietz, M. G. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0316-z · Cited by 52
Gui, J., Guo, Z., & Wu, D. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03532-2 · Cited by 41
“The BRAF mutations are also common in benign nevi [58].”
BackgroundBRAFmutation testing in clinical practice
Ziai, J. M., & Hui, P. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.1 · Cited by 43
Sherman, M. Y., Le, M., Stampfer, M. R., Gabai, V. L., & Yaglom, J. A. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00736.x · Cited by 41
“BRafV600E mutation harbor senescent melanocytes and rarely progress to melanomas (Pollock et al., 2003).”
BackgroundMolecular Markers of Tumor Progression in Melanoma
Rother, J., & Jones, D. (2009) · Current Genomics · doi:10.2174/138920209788488526 · Cited by 43
“KIT gene amplification also occurs [21, 27].”
BackgroundTanning and Increased Nevus Development in Very-Light-Skinned Children Without Red Hair
Aalborg, J., Morelli, J. G., Mokrohisky, S. T., Asdigian, N. L., Byers, T., Dellavalle, R. P., Box, N. F., & Crane, L. A. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.193 · Cited by 38
“In line with this, the recent discovery that BRAF mutations appear in up to 80% of common acquired nevi suggests that the RAS/RAF/ MAPK pathway is a common target for UV-induced mutations that initiate nevus formation.(31,32) Melanocytic nevi have been described as clonal amplifications of nevomelanocytes that have un…”
Broad spectrum identification of SUMO substrates in melanoma cells
Ganesan, A. K., Kho, Y., Kim, S. C., Chen, Y., Zhao, Y., & White, M. A. (2007) · PROTEOMICS · doi:10.1002/pmic.200600971 · Cited by 37
Hafner, C. M., Stoehr, R., van Oers, J. M. M., Zwarthoff, E. C., Hofstaedter, F., Klein, C. A., Landthaler, M., Hartmann, A., & VOGT, T. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.146 · Cited by 37
“In the past few years, it has become well known that melanocytic nevi frequently show the BRAF V600E hotspot mutation (Pollock et al., 2003).”
BackgroundBRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours
Serrano, C., Simonetti, S., Hernández‐Losa, J., Valverde, C. M., Carrato, C., Bagué, S., Orellana, R., Somoza, R., Moliné, T., Carles, J., et al. (2012) · Histopathology · doi:10.1111/his.12021 · Cited by 38
“For instance, human naevi are benign tumours of melanocytes that frequently harbour oncogenic mutations in BRAF.24 Remarkably, naevi typically remain in a growth-arrested state for decades and progress only rarely to melanoma due to oncogene-induced senescence.28,29 Similarly, the five BRAF- and KRASmutated schwanomma…”
BackgroundMouse models for BRAF-induced cancers
Pritchard, C. A., Carragher, L., Aldridge, V., Giblett, S. M., Jin, H., Foster, C., Andreadi, C., & Kamata, T. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351329 · Cited by 48
NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
Uguen, A., Talagas, M., Costa, S., Samaison, L., Paule, L., Alavi, Z., Braekeleer, M. D., Maréchal, C. L., & Marcorelles, P. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0359-0 · Cited by 36
“NRAS mutations, were classically reported to be nearly mutually exclusive to BRAF mutations, at least at the level of single cells, with only rare recently reported exceptions [18–22].”
BackgroundDecoding the Role of CD271 in Melanoma
Vidal, A., & Redmer, T. (2020) · Cancers · doi:10.3390/cancers12092460 · Cited by 42
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 39
Lade‐Keller, J., Riber‐Hansen, R., Guldberg, P., Schmidt, H., Hamilton-Dutoit, S. J., & Steiniche, T. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-202127 · Cited by 40
Flaherty, K. T. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e5357 · Cited by 37
“Specifically, BRAF mutations have been identified in a large proportion of benign nevi.(25,26) Given that nearly all such lesions will not subsequently transform into melanoma, it appeared that BRAF mutation might be necessary, but not sufficient for invasive melanoma to occur.”
BackgroundRecent Advances in the Biology, Therapy and Management of Melanoma
Davids, L. M. (2013) · InTech eBooks · doi:10.5772/46052 · Cited by 38
Goedert, L., Plaça, J. R., Fuziwara, C. S., Machado, M. C. R., Plaça, D. R., Almeida, P. P., Sanches, T. P., dos Santos, J. F., Corveloni, A. C., Pereira, I. E. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01957-0 · Cited by 36
Molecular Diagnostics in Melanoma: Current Status and Perspectives
Dadras, S. S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0623-rar1.1 · Cited by 38
Jovanovic, B., Egyházi, S., Eskandarpour, M., Ghiorzo, P., Palmer, J. M., Bianchi‐Scarrà, G., Hayward, N. K., & Hansson, J. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.287 · Cited by 39
“However, Pollock et al. (2003) observed concomitant NRAS and BRAF V600E mutations in 9% of nevi and suggested that this might be because of different clonal nests of cells within these tumors carrying distinct mutations, a possibility that could also explain our findings, although, intriguingly,…”
BackgroundResultSelf-citationTaking Human Cancer Genes to the Fish: A Transgenic Model of Melanoma in Zebrafish
Patton, E. E., & Zon, L. I. (2005) · Zebrafish · doi:10.1089/zeb.2005.1.363 · Cited by 38
“The pathological phenotype of the melanocytic lesions, coupled with the importance of BRAF mutations in human nevi, 11 led us to believe that these were the fish equivalent of human nevi: we named these lesions fish (f)-nevi.”
Familial clustering of giant congenital melanocytic nevi
de Wijn, R. S., Zaal, L. H., Hennekam, R. C. M., & van der Horst, C. M. A. M. (2009) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2009.02.090 · Cited by 36
B-RAF and melanocytic neoplasia
Gill, M., & Celebi, J. T. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.04.013 · Cited by 37
Molecular Pathogenesis of Sporadic Melanoma and Melanoma-Initiating Cells
Kong, Y., Kumar, S. M., & Xu, X. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0418-rar.1 · Cited by 43
Melanoma Biomarkers: Current Status and Utility in Diagnosis, Prognosis, and Response to Therapy
Haass, N. K., & Smalley, K. S. M. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256334 · Cited by 38
“Studies have shown that BRAF V600E mutations are highly prevalent in otherwise unsuspicious benign nevi,([96]) and this is not necessarily correlated with future melanoma development.”
BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level
Helmke, B. M., Mollenhauer, J., Herold‐Mende, C. C., Benner, A., Thome, M., Gaßler, N., Wahl, W., Lyer, S., Poustka, A., Otto, H. F., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.051 · Cited by 40
The immune‐related role of BRAF in melanoma
Tomei, S., Bedognetti, D., Giorgi, V. D., Sommariva, M., Civini, S., Reinboth, J., Hashmi, M. A., Ascierto, M. L., Liu, Q., Ayotte, B. D., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.014 · Cited by 38
The molecular pathology of cutaneous melanoma
Bogenrieder, T., & Herlyn, M. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0164 · Cited by 40
“Interestingly, however, a high frequency of BRAF V600E mutations (73–82%) has also been reported in common benign naevi, suggesting that BRAF activation might be the critical inducer of these benign ‘precursor’ lesions [51–53].”
BackgroundTrajectories of premalignancy during the journey from melanocyte to melanoma
Colebatch, A. J., & Scolyer, R. A. (2017) · Pathology · doi:10.1016/j.pathol.2017.09.002 · Cited by 43
The FBXO4 Tumor Suppressor Functions as a Barrier to Braf V600E -Dependent Metastatic Melanoma
Lee, E. K., Lian, Z., D'Andrea, K. P., Letrero, R., Sheng, W., Liu, S., Diehl, J. A., Pytel, D., Barbash, O., Schuchter, L. M., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00706-13 · Cited by 39
“all cutaneous melanomas (4) and by the impressive cytotoxicity”
BackgroundPirin Inhibits Cellular Senescence in Melanocytic Cells
Licciulli, S., Luise, C., Scafetta, G., Capra, M. C., Giardina, G., Nuciforo, P. G., Bòsari, S., Viale, G., Mazzarol, G., Tonelli, C., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.019 · Cited by 35
Lack of BRAFV600E Mutations in Giant Congenital Melanocytic Nevi in a Chinese Population
Wu, D., Wang, M., Wang, X., Yin, N., Song, T., Li, H., Yu, J., Wang, D.-M., & Zhao, Z. (2011) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181fb5bc7 · Cited by 36
“Previous studies reported various results in BRAF mutations in CMNs, without considering the size of nevi.(2,16) Recently, it was noticed that the frequencies of BRAF mutations vary with the size of CMNs.”
BackgroundResultERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma
Ryan, M. B., Finn, A. J., Pedone, K. H., Thomas, N. E., Der, C. J., & Cox, A. D. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0184 · Cited by 37
“Since BRAF and NRAS mutations are found in a high percentage of nevi (28,29), it is not surprising to find PREX1 in nevi as well as in melanoma tissue.”
BackgroundHennessey, R. C., Holderbaum, A. M., Bonilla, A., Delaney, C. P., Gillahan, J. E., Tober, K. L., Oberyszyn, T. M., Zippin, J. H., & Burd, C. E. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12601 · Cited by 35
“…codon 600 variants) are not characterized by a UV signature and are found frequently in benign melanocytic nevi (i.e., moles), including those present at birth (Bauer, Curtin, Pinkel, & Bastian, 2007; Hodis et al., 2012; Pollock et al., 2003; Poynter et al., 2006; Ross, Sanchez, & Grichnik, 2011).”
MicroRNAs in the pathogenesis of malignant melanoma
Glud, M., & Gniadecki, R. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04579.x · Cited by 42
Hong, J. W., Lee, S., Kim, D.-C., Kim, K., & Song, K. (2014) · Annals of Dermatology · doi:10.5021/ad.2014.26.2.195 · Cited by 37
The genetics of malignant melanoma
Lomas, J., Martín‐Duque, P., Pons, M., & Quintanilla, M. (2008) · Frontiers in bioscience · doi:10.2741/3065 · Cited by 40
“BRAF mutations are common in benign and dysplastic nevi (72, 77), pointing to a potential initiating role of BRAF in melanocyte transformation.”
BackgroundBRAF — A new player in hematological neoplasms
Machnicki, M. M., & Stokłosa, T. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.01.001 · Cited by 34
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma
Ni, T. K., Landrette, S. F., Bjornson, R. D., Bosenberg, M., & Xu, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314435110 · Cited by 36
“In humans, benign nevi and malignant melanomas frequently harbor the oncogenic BRAF mutation (24, 25).”
BackgroundBRAF V600E mutational status in bile duct adenomas and hamartomas
Pujals, A., Bioulac‐Sage, P., Castain, C., Charpy, C., Zafrani, É. S., & Caldéraro, J. (2015) · Histopathology · doi:10.1111/his.12674 · Cited by 34
Melanoma Mutagenesis and Aberrant Cell Signaling
Bello, D. M., Ariyan, C. E., & Carvajal, R. D. (2013) · Cancer Control · doi:10.1177/107327481302000404 · Cited by 40
Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
Obaid, N., Bedard, K., & Huang, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030585 · Cited by 39
“Mutations in BRAF have also been found in a pre-malignant colon polyps [12], as well as benign skin lesions [13,14].”
BackgroundRuiz, R., Chen, C., Razzak, E., Vasudeva, P., Krasieva, T. B., Shiu, J., Caldwell, M. G., Yan, H., Lowengrub, J. S., Ganesan, A. K., et al. (2020) · eLife · doi:10.7554/elife.61026 · Cited by 39
“Curiously, the same mutation is found in 89% of melanocytic nevi (Pollock et al., 2003)—the benign, pigmented ‘moles’ found on the skin of most individuals.”
BackgroundNell, R. J., Menger, N. V., Versluis, M., Luyten, G. P. M., Verdijk, R. M., Madigan, M. C., Jager, M. J., & van der Velden, P. A. (2021) · BMC Cancer · doi:10.1186/s12885-021-07865-x · Cited by 34
The Genomic Landscape of Melanoma and Its Therapeutic Implications
Yang, T., Yu, S., Ke, C. K., & Cheng, S. (2023) · Genes · doi:10.3390/genes14051021 · Cited by 36
“For example, BRAF mutation alone is not sufficient for inducing melanoma as BRAF mutations are frequently observed in benign nevi [50,51].”
BackgroundRodriguez‐Viciana, P., & Rauen, K. A. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)38019-1 · Cited by 34
Dhomen, N. S., Dias, S. D. R., Hayward, R., Ogilvie, L. M., Hedley, D., Delmas, V., McCarthy, A., Henderson, D. J., Springer, C. J., Pritchard, C. A., et al. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00662.x · Cited by 47
“It is therefore surprising that BRAF is also mutated in up to 80% of common human naevi (Pollock et al., 2003), acquired melanocytic lesions that can remain benign for several decades.”
BackgroundSomatic mutations in GNAQ in amelanotic/hypomelanotic blue nevi
Emley, A., Nguyen, L., Yang, S., & Mahalingam, M. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.05.027 · Cited by 34
Ball, N. J., & Kho, G. T. (2005) · Journal of Cutaneous Pathology · doi:10.1111/j.0303-6987.2005.00376.x · Cited by 34
“Altered ras signal transduction has been implicated in the biology of melanocytic nevi and melanomas.(8,9) An association between neurofibromatosis, type 1 and increased numbers of ordinary nevi might be expected based on these findings.”
BackgroundHohenauer, T., Berking, C., Schmidt, A., Haferkamp, S., Senft, D., Kammerbauer, C., Fraschka, S. A. K., Graf, S. A., Irmler, M., Beckers, J., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201862 · Cited by 35
“Elevated RAS/RAF signalling due to oncogenic mutations in BRAF or NRAS is well studied in melanoma, but these mutations are also common in non-proliferating senescent nevi (Pollock et al, 2003).”
Nunnari, G., Xu, Y., Acheampong, E. A., Fang, J., Daniel, R., Zhang, C., Zhang, H., Mukhtār, M., & Pomerantz, R. J. (2005) · Journal of NeuroVirology · doi:10.1080/13550280500187005 · Cited by 33
Applications of Genomics in Melanoma Oncogene Discovery
Berger, M. F., & Garraway, L. A. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.005 · Cited by 37
“melanocytic nevi, whereas MITF amplification is restricted to malignant melanoma.(29,44) This suggests that BRAF mutations occur early during melanoma progression, perhaps predisposing cells to hyperproliferation following additional genetic”
The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
Nissan, M. H., & Solit, D. B. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0198-4 · Cited by 35
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Colombino, M., Lissia, A., Capone, M., GIORGI, V. D., Massi, D., Stanganelli, I., Fonsatti, E., Maio, M., Botti, G., Caracò, C., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-202 · Cited by 37
“Furthermore, the presence of BRAF mutations in nevi [13-15] suggests that activation of the RAS/RAF/MEK/ERK pathway may participate to initiation of melanocytic transformation as well as that BRAF activation is necessary for inducing cell proliferation but not sufficient for the development of melanoma (additional mol…”
BackgroundZecena, H., Tveit, D. M., Wang, Z., Farhat, A. M., Panchal, P., Liu, J., Singh, S. J., Sanghera, A., Bainiwal, A., Teo, S. Y., et al. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0554-1 · Cited by 38
“In malignant melanoma, activating point-mutations in the mitogen activated protein kinase (MAPK) pathway in BRAF kinase (B-Raf proto-oncogene, serine/threonine kinase, Gene ID: 673) [1-3] made it possible to develop potent kinase inhibitors matched to genotyped kinase mutations in precision medicine approaches [4-6].”
BackgroundMolecular diagnosis in dermatopathology: What makes sense, and what doesn’t
Braun‐Falco, M., Schempp, W., & Weyers, W. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00805.x · Cited by 36
The T1799A point mutation is present in posterior uveal melanoma
Janssen, C. S., Sibbett, R., Henriquez, F. L., McKay, I. C., Kemp, E., & Roberts, F. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604731 · Cited by 33
“These mutations have been shown to be present in 66 to 80% of cutaneous melanomas and have also been detected in up to 82% of melanocytic nevi(Pollock et al, 2003).”
BackgroundPoint mutations of protein kinases and individualised cancer therapy
Davies, M. A., Hennessy, B. T., & Mills, G. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.16.2243 · Cited by 37
Wangari‐Talbot, J., & Chen, S. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2012.00330 · Cited by 42
“%) with the highest incidences found in malignant melanoma (27–70%), papillary thyroid cancer (36–53%), colorectal cancer (5–22%), and serous ovarian cancer (30%; Davies et al., 2002; Kumar et al., 2003; Pollock et al., 2003a; Young et al., 2005).”
BackgroundInfluentialStrzemski, M., Wojnicki, K., Sowa, I., Wojas‐Krawczyk, K., Krawczyk, P. A., Kocjan, R., Such, J., Latalski, M., Wnorowski, A., & Wójciak, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00371 · Cited by 33
“, 2012), a mutation common in melanomas (Moses et al., 2003).”
BackgroundGeffrotin, C., Créchet, F., Roy, P. L., Chalony, C. L., Leplat, J. J. J. J., Iannuccelli, N., Barbosa, A. S., Renard, C., Gruand, J., Milan, D., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20053 · Cited by 33
Indsto, J. O., Kumar, S., Wang, L., Crotty, K. A., Arbuckle, S. M., & Mann, G. J. (2006) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00646.x · Cited by 33
BRAFV600EProtein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases
Eriksson, H., Zebary, A., Vassilaki, I., Omholt, K., Ghaderi, M., & Hansson, J. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.3689 · Cited by 32
Held, L., Eigentler, T., Metzler, G., Leiter, U., Messina, J. L., Glass, L. F., Garbe, C., & Bauer, J. M. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.11.010 · Cited by 32
Pin, F., Buron, F., Saab, F., Colliandre, L., Bourg, S., Schoentgen, F., Guével, R. L., Guguen‐Guillouzo, C., & Routier, S. (2011) · MedChemComm · doi:10.1039/c1md00141h · Cited by 34
Liquid biopsy to monitor melanoma patients
Gaiser, M. R., von Bubnoff, N. C. C., Gebhardt, C., & Utikal, J. S. (2018) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13461 · Cited by 37
Cancer progression as a learning process
Shomar, A., Barak, O., & Brenner, N. (2022) · iScience · doi:10.1016/j.isci.2022.103924 · Cited by 40
Recurrent driver mutations in benign tumors
Gomes, C. C. (2022) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2022.108412 · Cited by 33
Havas, A. P., Yin, S., & Adams, P. D. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13302 · Cited by 35
Absence of Senescence-Associated β-Galactosidase Activity in Human Melanocytic Nevi In Vivo
Cotter, M. A., Florell, S. R., Leachman, S. A., & Grossman, D. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700903 · Cited by 36
“Senescence may also occur independent of telomere shortening, through expression of single oncogenes (such as members of the Ras pathway) in otherwise genetically intact cells including melanocytes (Serrano et al., 1997; Pollock et al., 2003).”
BackgroundIssues affecting molecular staging in the management of patients with melanoma
Palmieri, G., Casula, M., Sini, M. C., Ascierto, P. A., & Cossu, A. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00091.x · Cited by 38
“Presence of BRAF mutations in benign and dysplastic nevi supports the hypothesis that activation of the RAF/MEK/ERK pathway is an early event in melanoma progression and that additional co-operating genetic events are required to achieve full malignancy [108].”
BackgroundFarber, M. J., Heilman, E. R., & Friedman, R. J. (2012) · Dermatologic Clinics · doi:10.1016/j.det.2012.04.004 · Cited by 33
“For example, BRAF mutations are common in dysplastic nevi and melanoma but are also seen with similar frequency in benign melanocytic nevi.(86) Many experts posit that the similar genetic mutations in dysplastic nevi and melanoma place dysplastic nevi along a continuum between banal nevi and melanoma.”
BackgroundGenetic Mutations Involved in Melanoma: A Summary of Our Current Understanding
High, W. A., & Robinson, W. A. (2007) · Advances in Dermatology · doi:10.1016/j.yadr.2007.07.009 · Cited by 39
BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii
Flavin, R., Smyth, P. C., Crotty, P. L., Finn, S. P., Cahill, S., Denning, K. M., Li, J., O’Regan, E. M., O’Leary, J. J., & Sheils, O. M. (2007) · International Journal of Surgical Pathology · doi:10.1177/1066896906299131 · Cited by 32
Predictors of BRAF Mutation in Melanocytic Nevi
Karram, S., Novy, M., Saroufim, M., Loya, A., Taraif, S., Houreih, M. A., Rauscher, B., Habib, R., Oberkanins, C., & Khalifeh, I. M. (2012) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e31826db181 · Cited by 31
“BRAF mutations, through activation of the RAS–RAF– MEK–ERK–MAP kinase pathway, have been determined as a critical step in the development of melanocytic neoplasia.(8,16) Multiple studies have demonstrated BRAF mutations in both nevi and melanoma.”
BackgroundResultDeLeon, T., Almquist, D., Kipp, B. R., Langlais, B., Mangold, A. R., Winters, J. L., Kosiorek, H., Joseph, R. W., Dronca, R. S., Block, M. S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230306 · Cited by 31
“Both BRAFmutations (BRAF) and NRASmutations (NRAS) have been shown to be early events that occur in benign and pre-invasive lesions and are not sufficient to induce carcinogenesis [4,5].”
BackgroundFrom Tank to Treatment: Modeling Melanoma in Zebrafish
Frantz, W. T., & Ceol, C. J. (2020) · Cells · doi:10.3390/cells9051289 · Cited by 38
“However, these mutations alone are not sufficient to give rise to malignancy, as human nevi frequently express BRAFV600E [20].”
BackgroundThe Morpho-Molecular Landscape of Spitz Neoplasms
Pozzo, C. A. D., & Cappellesso, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084211 · Cited by 32
Zhao, Y., Zhang, Y., Yang, Z., Li, A., & Dong, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.148 · Cited by 33
“Using various mutation assays, we and others reported high frequencies (approximately 70%) of BRAF mutations in benign melanocytic nevi (Dong et al., 2003; Pollock et al., 2003).”
BackgroundActivation of the MAP Kinase Pathway Induces Apoptosis in the Merkel Cell Carcinoma Cell Line UISO
Houben, R., Ortmann, S., Schrama, D., Herold, M. J., Berberich, I., Reichardt, H. M., & Becker, J. C. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700857 · Cited by 35
“On the other hand, MAP kinase pathway activation by itself is not sufficient for malignant transformation, as high frequencies of activating B-Raf mutations are also found in benign nevi (Pollock et al., 2003).”
BackgroundGos, A., Jurkowska, M., van Akkooi, A. C. J., Robert, C., Koseła-Paterczyk, H., Koljenović, S., Kamsu-Kom, N., Michej, W., Jeziorski, A., Pluta, P., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3799-y · Cited by 33
“The important role of BRAF alternations in melanoma development is proven; however, the mutation itself is not sufficient for malignant transformation, and BRAF mutations also occur with high frequency in benign nevi.(15) The frequency of NRAS mutation in melanoma of cutaneous origin varies between 15 and 30 %.”
BackgroundThe Power Behind the Throne: Senescence and the Hallmarks of Cancer
Hoare, M., & Narita, M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050352 · Cited by 33
McEvoy, A. C., Pereira, M. R., Reid, A. L., Pearce, R. L., Cowell, L., Al‐Ogaili, Z., Khattak, M. A., Millward, M., Meniawy, T. M., Gray, E. S., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26451 · Cited by 31
“In addition, given that 82% of benign melanocytic nevi carry BRAF mutations [42], we tested a cohort of healthy controls with ≥50 nevi for BRAF V600E and BRAF V600K mutant specific cfDNA (Supplementary Table 1).”
Recurring HRAS mutation G12S in Dutch patients with Costello syndrome
Steensel, M. A. M. V., Vreeburg, M., Peels, C. H., van Ravenswaaij‐Arts, C. M. A., Bijlsma, E. K., Schrander-Stumpel, C. T. R. M., & Steensel, M. A. M. V. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00474.x · Cited by 31
“Aneurysm-lentiginosis syndrome (8) comes to mind, as melanocytic proliferations are associated with activation of the RAS/RAF/MAPK pathway (9,10) and vascular aneurysms have also been described in Noonan syndrome (11,12).”
BackgroundFernández‐Barral, A., Orgaz, J. L., Baquero, P., Ali, Z., Moreno, A., Tiana, M., Gómez, V., Riveiro‐Falkenbach, E., Cañadas, C., Zazo, S., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.06.001 · Cited by 33
“In support of the physiological relevance of this result, benign naevi; which are considered senescent lesions [32,33], consistently showed decreased levels of both PEDF and MITF compared to primary melanomas.”
ResultUnraveling the Intricacies of Autophagy and Mitophagy: Implications in Cancer Biology
Lee, S., Son, J.-Y., Lee, J., & Cheong, H. (2023) · Cells · doi:10.3390/cells12232742 · Cited by 35
DEK expression in melanocytic lesions
Kappes, F., Khodadoust, M. S., Yu, L., Kim, D. S. L., Fullen, D. R., Markovitz, D. M., & Ma, L. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.10.022 · Cited by 30
“It has been demonstrated that benign nevi frequently contain oncogenic mutations in BRAF, yet remain arrested in a state of cellular senescence [26].”
Melanocytomas of the C entral N ervous S ystem: a clinicopathological and molecular study
Wang, H., Zhang, S., Wu, C., Zhang, Z., & Qin, T. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12109 · Cited by 34
Molecular classification and biomarker discovery in papillary thyroid carcinoma
Sheils, O. M. (2005) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.5.6.927 · Cited by 30
Shinohara, S., & Rothstein, J. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207964 · Cited by 30
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.